

# Global Recombinant Non-Glycosylated Proteins Biosimilars Market 2024 by Company, Regions, Type and Application, Forecast to 2030

<https://marketpublishers.com/r/G3A99C09280FEN.html>

Date: July 2024

Pages: 105

Price: US\$ 3,480.00 (Single User License)

ID: G3A99C09280FEN

## Abstracts

According to our (Global Info Research) latest study, the global Recombinant Non-Glycosylated Proteins Biosimilars market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Recombinant non-glycosylated proteins include human growth hormone, granulocyte colony-stimulating factor, interferons, and insulin. The statistic scope in this report is Recombinant non-glycosylated proteins biosimilars.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Recombinant Non-Glycosylated Proteins Biosimilars industry chain, the market status of Oncology (Insulin, rHGH), Chronic Diseases (Insulin, rHGH), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Recombinant Non-Glycosylated Proteins Biosimilars.

Regionally, the report analyzes the Recombinant Non-Glycosylated Proteins Biosimilars markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Recombinant Non-Glycosylated Proteins Biosimilars market, with robust domestic demand, supportive policies, and a strong manufacturing base.

#### Key Features:

The report presents comprehensive understanding of the Recombinant Non-Glycosylated Proteins Biosimilars market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Recombinant Non-Glycosylated Proteins Biosimilars industry.

The report involves analyzing the market at a macro level:

**Market Sizing and Segmentation:** Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Insulin, rHGH).

**Industry Analysis:** Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Recombinant Non-Glycosylated Proteins Biosimilars market.

**Regional Analysis:** The report involves examining the Recombinant Non-Glycosylated Proteins Biosimilars market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

**Market Projections:** Report covers the gathered data and analysis to make future projections and forecasts for the Recombinant Non-Glycosylated Proteins Biosimilars market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Recombinant Non-Glycosylated Proteins Biosimilars:

**Company Analysis:** Report covers individual Recombinant Non-Glycosylated Proteins Biosimilars players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

**Consumer Analysis:** Report covers data on consumer behaviour, preferences, and attitudes towards Recombinant Non-Glycosylated Proteins Biosimilars. This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Oncology, Chronic Diseases).

**Technology Analysis:** Report covers specific technologies relevant to Recombinant Non-Glycosylated Proteins Biosimilars. It assesses the current state, advancements, and potential future developments in Recombinant Non-Glycosylated Proteins Biosimilars areas.

**Competitive Landscape:** By analyzing individual companies, suppliers, and consumers, the report presents insights into the competitive landscape of the Recombinant Non-Glycosylated Proteins Biosimilars market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

**Market Validation:** The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

## Market Segmentation

Recombinant Non-Glycosylated Proteins Biosimilars market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

## Market segment by Type

Insulin

rHGH

Interferon

### Market segment by Application

Oncology

Chronic Diseases

Autoimmune Diseases

Blood Disorders

Growth Hormone Deficiency

Infectious Diseases

Other Diseases

### Market segment by players, this report covers

Sandoz

Pfizer

Teva Pharmaceutical

Celltrion

Biocon

Amgen

Samsung Biologics

Mylan

Dr. Reddy's Laboratories

Stada Arzneimittel AG

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Argentina and Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Recombinant Non-Glycosylated Proteins Biosimilars product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Recombinant Non-Glycosylated Proteins Biosimilars, with revenue, gross margin and global market share of Recombinant Non-Glycosylated Proteins Biosimilars from 2019 to 2024.

Chapter 3, the Recombinant Non-Glycosylated Proteins Biosimilars competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with

revenue and market share for key countries in the world, from 2019 to 2024. and Recombinant Non-Glycosylated Proteins Biosimilars market forecast, by regions, type and application, with consumption value, from 2025 to 2030.

Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Recombinant Non-Glycosylated Proteins Biosimilars.

Chapter 13, to describe Recombinant Non-Glycosylated Proteins Biosimilars research findings and conclusion.

## Contents

### 1 MARKET OVERVIEW

#### 1.1 Product Overview and Scope of Recombinant Non-Glycosylated Proteins

##### Biosimilars

#### 1.2 Market Estimation Caveats and Base Year

#### 1.3 Classification of Recombinant Non-Glycosylated Proteins Biosimilars by Type

##### 1.3.1 Overview: Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type: 2019 Versus 2023 Versus 2030

##### 1.3.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value Market Share by Type in 2023

##### 1.3.3 Insulin

##### 1.3.4 rHGH

##### 1.3.5 Interferon

#### 1.4 Global Recombinant Non-Glycosylated Proteins Biosimilars Market by Application

##### 1.4.1 Overview: Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application: 2019 Versus 2023 Versus 2030

##### 1.4.2 Oncology

##### 1.4.3 Chronic Diseases

##### 1.4.4 Autoimmune Diseases

##### 1.4.5 Blood Disorders

##### 1.4.6 Growth Hormone Deficiency

##### 1.4.7 Infectious Diseases

##### 1.4.8 Other Diseases

#### 1.5 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size & Forecast

#### 1.6 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Forecast by Region

##### 1.6.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Region: 2019 VS 2023 VS 2030

##### 1.6.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Region, (2019-2030)

##### 1.6.3 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Prospect (2019-2030)

##### 1.6.4 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Prospect (2019-2030)

##### 1.6.5 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Prospect (2019-2030)

##### 1.6.6 South America Recombinant Non-Glycosylated Proteins Biosimilars Market Size

and Prospect (2019-2030)

1.6.7 Middle East and Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Prospect (2019-2030)

## **2 COMPANY PROFILES**

### **2.1 Sandoz**

2.1.1 Sandoz Details

2.1.2 Sandoz Major Business

2.1.3 Sandoz Recombinant Non-Glycosylated Proteins Biosimilars Product and Solutions

2.1.4 Sandoz Recombinant Non-Glycosylated Proteins Biosimilars Revenue, Gross Margin and Market Share (2019-2024)

2.1.5 Sandoz Recent Developments and Future Plans

### **2.2 Pfizer**

2.2.1 Pfizer Details

2.2.2 Pfizer Major Business

2.2.3 Pfizer Recombinant Non-Glycosylated Proteins Biosimilars Product and Solutions

2.2.4 Pfizer Recombinant Non-Glycosylated Proteins Biosimilars Revenue, Gross Margin and Market Share (2019-2024)

2.2.5 Pfizer Recent Developments and Future Plans

### **2.3 Teva Pharmaceutical**

2.3.1 Teva Pharmaceutical Details

2.3.2 Teva Pharmaceutical Major Business

2.3.3 Teva Pharmaceutical Recombinant Non-Glycosylated Proteins Biosimilars Product and Solutions

2.3.4 Teva Pharmaceutical Recombinant Non-Glycosylated Proteins Biosimilars Revenue, Gross Margin and Market Share (2019-2024)

2.3.5 Teva Pharmaceutical Recent Developments and Future Plans

### **2.4 Celltrion**

2.4.1 Celltrion Details

2.4.2 Celltrion Major Business

2.4.3 Celltrion Recombinant Non-Glycosylated Proteins Biosimilars Product and Solutions

2.4.4 Celltrion Recombinant Non-Glycosylated Proteins Biosimilars Revenue, Gross Margin and Market Share (2019-2024)

2.4.5 Celltrion Recent Developments and Future Plans

### **2.5 Biocon**



- 2.5.1 Biocon Details
- 2.5.2 Biocon Major Business
- 2.5.3 Biocon Recombinant Non-Glycosylated Proteins Biosimilars Product and Solutions
- 2.5.4 Biocon Recombinant Non-Glycosylated Proteins Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
- 2.5.5 Biocon Recent Developments and Future Plans
- 2.6 Amgen
  - 2.6.1 Amgen Details
  - 2.6.2 Amgen Major Business
  - 2.6.3 Amgen Recombinant Non-Glycosylated Proteins Biosimilars Product and Solutions
  - 2.6.4 Amgen Recombinant Non-Glycosylated Proteins Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
  - 2.6.5 Amgen Recent Developments and Future Plans
- 2.7 Samsung Biologics
  - 2.7.1 Samsung Biologics Details
  - 2.7.2 Samsung Biologics Major Business
  - 2.7.3 Samsung Biologics Recombinant Non-Glycosylated Proteins Biosimilars Product and Solutions
  - 2.7.4 Samsung Biologics Recombinant Non-Glycosylated Proteins Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
  - 2.7.5 Samsung Biologics Recent Developments and Future Plans
- 2.8 Mylan
  - 2.8.1 Mylan Details
  - 2.8.2 Mylan Major Business
  - 2.8.3 Mylan Recombinant Non-Glycosylated Proteins Biosimilars Product and Solutions
  - 2.8.4 Mylan Recombinant Non-Glycosylated Proteins Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
  - 2.8.5 Mylan Recent Developments and Future Plans
- 2.9 Dr. Reddy's Laboratories
  - 2.9.1 Dr. Reddy's Laboratories Details
  - 2.9.2 Dr. Reddy's Laboratories Major Business
  - 2.9.3 Dr. Reddy's Laboratories Recombinant Non-Glycosylated Proteins Biosimilars Product and Solutions
  - 2.9.4 Dr. Reddy's Laboratories Recombinant Non-Glycosylated Proteins Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
  - 2.9.5 Dr. Reddy's Laboratories Recent Developments and Future Plans

## 2.10 Stada Arzneimittel AG

### 2.10.1 Stada Arzneimittel AG Details

### 2.10.2 Stada Arzneimittel AG Major Business

### 2.10.3 Stada Arzneimittel AG Recombinant Non-Glycosylated Proteins Biosimilars Product and Solutions

### 2.10.4 Stada Arzneimittel AG Recombinant Non-Glycosylated Proteins Biosimilars Revenue, Gross Margin and Market Share (2019-2024)

### 2.10.5 Stada Arzneimittel AG Recent Developments and Future Plans

## 3 MARKET COMPETITION, BY PLAYERS

### 3.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue and Share by Players (2019-2024)

### 3.2 Market Share Analysis (2023)

#### 3.2.1 Market Share of Recombinant Non-Glycosylated Proteins Biosimilars by Company Revenue

#### 3.2.2 Top 3 Recombinant Non-Glycosylated Proteins Biosimilars Players Market Share in 2023

#### 3.2.3 Top 6 Recombinant Non-Glycosylated Proteins Biosimilars Players Market Share in 2023

### 3.3 Recombinant Non-Glycosylated Proteins Biosimilars Market: Overall Company Footprint Analysis

#### 3.3.1 Recombinant Non-Glycosylated Proteins Biosimilars Market: Region Footprint

#### 3.3.2 Recombinant Non-Glycosylated Proteins Biosimilars Market: Company Product Type Footprint

#### 3.3.3 Recombinant Non-Glycosylated Proteins Biosimilars Market: Company Product Application Footprint

### 3.4 New Market Entrants and Barriers to Market Entry

### 3.5 Mergers, Acquisition, Agreements, and Collaborations

## 4 MARKET SIZE SEGMENT BY TYPE

### 4.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value and Market Share by Type (2019-2024)

### 4.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Forecast by Type (2025-2030)

## 5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value Market Share by Application (2019-2024)

5.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Forecast by Application (2025-2030)

## **6 NORTH AMERICA**

6.1 North America Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Type (2019-2030)

6.2 North America Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Application (2019-2030)

6.3 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country

6.3.1 North America Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Country (2019-2030)

6.3.2 United States Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Forecast (2019-2030)

6.3.3 Canada Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Forecast (2019-2030)

6.3.4 Mexico Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Forecast (2019-2030)

## **7 EUROPE**

7.1 Europe Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Type (2019-2030)

7.2 Europe Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Application (2019-2030)

7.3 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country

7.3.1 Europe Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Country (2019-2030)

7.3.2 Germany Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Forecast (2019-2030)

7.3.3 France Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Forecast (2019-2030)

7.3.4 United Kingdom Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Forecast (2019-2030)

7.3.5 Russia Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Forecast (2019-2030)

7.3.6 Italy Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Forecast (2019-2030)

## **8 ASIA-PACIFIC**

8.1 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Type (2019-2030)

8.2 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Application (2019-2030)

8.3 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Region

8.3.1 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Region (2019-2030)

8.3.2 China Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Forecast (2019-2030)

8.3.3 Japan Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Forecast (2019-2030)

8.3.4 South Korea Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Forecast (2019-2030)

8.3.5 India Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Forecast (2019-2030)

8.3.6 Southeast Asia Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Forecast (2019-2030)

8.3.7 Australia Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Forecast (2019-2030)

## **9 SOUTH AMERICA**

9.1 South America Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Type (2019-2030)

9.2 South America Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Application (2019-2030)

9.3 South America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country

9.3.1 South America Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Country (2019-2030)

9.3.2 Brazil Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Forecast (2019-2030)

9.3.3 Argentina Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Forecast (2019-2030)

Forecast (2019-2030)

## **10 MIDDLE EAST & AFRICA**

10.1 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Type (2019-2030)

10.2 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Application (2019-2030)

10.3 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country

10.3.1 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Country (2019-2030)

10.3.2 Turkey Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Forecast (2019-2030)

10.3.3 Saudi Arabia Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Forecast (2019-2030)

10.3.4 UAE Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Forecast (2019-2030)

## **11 MARKET DYNAMICS**

11.1 Recombinant Non-Glycosylated Proteins Biosimilars Market Drivers

11.2 Recombinant Non-Glycosylated Proteins Biosimilars Market Restraints

11.3 Recombinant Non-Glycosylated Proteins Biosimilars Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

## **12 INDUSTRY CHAIN ANALYSIS**

12.1 Recombinant Non-Glycosylated Proteins Biosimilars Industry Chain

12.2 Recombinant Non-Glycosylated Proteins Biosimilars Upstream Analysis

12.3 Recombinant Non-Glycosylated Proteins Biosimilars Midstream Analysis

12.4 Recombinant Non-Glycosylated Proteins Biosimilars Downstream Analysis

## **13 RESEARCH FINDINGS AND CONCLUSION**

## **14 APPENDIX**

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Type, (USD Million), 2019 & 2023 & 2030

Table 2. Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Application, (USD Million), 2019 & 2023 & 2030

Table 3. Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Region (2019-2024) & (USD Million)

Table 4. Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Region (2025-2030) & (USD Million)

Table 5. Sandoz Company Information, Head Office, and Major Competitors

Table 6. Sandoz Major Business

Table 7. Sandoz Recombinant Non-Glycosylated Proteins Biosimilars Product and Solutions

Table 8. Sandoz Recombinant Non-Glycosylated Proteins Biosimilars Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 9. Sandoz Recent Developments and Future Plans

Table 10. Pfizer Company Information, Head Office, and Major Competitors

Table 11. Pfizer Major Business

Table 12. Pfizer Recombinant Non-Glycosylated Proteins Biosimilars Product and Solutions

Table 13. Pfizer Recombinant Non-Glycosylated Proteins Biosimilars Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 14. Pfizer Recent Developments and Future Plans

Table 15. Teva Pharmaceutical Company Information, Head Office, and Major Competitors

Table 16. Teva Pharmaceutical Major Business

Table 17. Teva Pharmaceutical Recombinant Non-Glycosylated Proteins Biosimilars Product and Solutions

Table 18. Teva Pharmaceutical Recombinant Non-Glycosylated Proteins Biosimilars Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 19. Teva Pharmaceutical Recent Developments and Future Plans

Table 20. Celltrion Company Information, Head Office, and Major Competitors

Table 21. Celltrion Major Business

Table 22. Celltrion Recombinant Non-Glycosylated Proteins Biosimilars Product and Solutions

Table 23. Celltrion Recombinant Non-Glycosylated Proteins Biosimilars Revenue (USD



Million), Gross Margin and Market Share (2019-2024)

Table 24. Celltrion Recent Developments and Future Plans

Table 25. Biocon Company Information, Head Office, and Major Competitors

Table 26. Biocon Major Business

Table 27. Biocon Recombinant Non-Glycosylated Proteins Biosimilars Product and Solutions

Table 28. Biocon Recombinant Non-Glycosylated Proteins Biosimilars Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 29. Biocon Recent Developments and Future Plans

Table 30. Amgen Company Information, Head Office, and Major Competitors

Table 31. Amgen Major Business

Table 32. Amgen Recombinant Non-Glycosylated Proteins Biosimilars Product and Solutions

Table 33. Amgen Recombinant Non-Glycosylated Proteins Biosimilars Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 34. Amgen Recent Developments and Future Plans

Table 35. Samsung Biologics Company Information, Head Office, and Major Competitors

Table 36. Samsung Biologics Major Business

Table 37. Samsung Biologics Recombinant Non-Glycosylated Proteins Biosimilars Product and Solutions

Table 38. Samsung Biologics Recombinant Non-Glycosylated Proteins Biosimilars Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 39. Samsung Biologics Recent Developments and Future Plans

Table 40. Mylan Company Information, Head Office, and Major Competitors

Table 41. Mylan Major Business

Table 42. Mylan Recombinant Non-Glycosylated Proteins Biosimilars Product and Solutions

Table 43. Mylan Recombinant Non-Glycosylated Proteins Biosimilars Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 44. Mylan Recent Developments and Future Plans

Table 45. Dr. Reddy's Laboratories Company Information, Head Office, and Major Competitors

Table 46. Dr. Reddy's Laboratories Major Business

Table 47. Dr. Reddy's Laboratories Recombinant Non-Glycosylated Proteins Biosimilars Product and Solutions

Table 48. Dr. Reddy's Laboratories Recombinant Non-Glycosylated Proteins Biosimilars Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 49. Dr. Reddy's Laboratories Recent Developments and Future Plans



Table 50. Stada Arzneimittel AG Company Information, Head Office, and Major Competitors

Table 51. Stada Arzneimittel AG Major Business

Table 52. Stada Arzneimittel AG Recombinant Non-Glycosylated Proteins Biosimilars Product and Solutions

Table 53. Stada Arzneimittel AG Recombinant Non-Glycosylated Proteins Biosimilars Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 54. Stada Arzneimittel AG Recent Developments and Future Plans

Table 55. Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue (USD Million) by Players (2019-2024)

Table 56. Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue Share by Players (2019-2024)

Table 57. Breakdown of Recombinant Non-Glycosylated Proteins Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3)

Table 58. Market Position of Players in Recombinant Non-Glycosylated Proteins Biosimilars, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023

Table 59. Head Office of Key Recombinant Non-Glycosylated Proteins Biosimilars Players

Table 60. Recombinant Non-Glycosylated Proteins Biosimilars Market: Company Product Type Footprint

Table 61. Recombinant Non-Glycosylated Proteins Biosimilars Market: Company Product Application Footprint

Table 62. Recombinant Non-Glycosylated Proteins Biosimilars New Market Entrants and Barriers to Market Entry

Table 63. Recombinant Non-Glycosylated Proteins Biosimilars Mergers, Acquisition, Agreements, and Collaborations

Table 64. Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value (USD Million) by Type (2019-2024)

Table 65. Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value Share by Type (2019-2024)

Table 66. Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value Forecast by Type (2025-2030)

Table 67. Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Application (2019-2024)

Table 68. Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value Forecast by Application (2025-2030)

Table 69. North America Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Type (2019-2024) & (USD Million)

Table 70. North America Recombinant Non-Glycosylated Proteins Biosimilars

Consumption Value by Type (2025-2030) & (USD Million)

Table 71. North America Recombinant Non-Glycosylated Proteins Biosimilars

Consumption Value by Application (2019-2024) & (USD Million)

Table 72. North America Recombinant Non-Glycosylated Proteins Biosimilars

Consumption Value by Application (2025-2030) & (USD Million)

Table 73. North America Recombinant Non-Glycosylated Proteins Biosimilars

Consumption Value by Country (2019-2024) & (USD Million)

Table 74. North America Recombinant Non-Glycosylated Proteins Biosimilars

Consumption Value by Country (2025-2030) & (USD Million)

Table 75. Europe Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Type (2019-2024) & (USD Million)

Table 76. Europe Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Type (2025-2030) & (USD Million)

Table 77. Europe Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Application (2019-2024) & (USD Million)

Table 78. Europe Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Application (2025-2030) & (USD Million)

Table 79. Europe Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Country (2019-2024) & (USD Million)

Table 80. Europe Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Country (2025-2030) & (USD Million)

Table 81. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Type (2019-2024) & (USD Million)

Table 82. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Type (2025-2030) & (USD Million)

Table 83. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Application (2019-2024) & (USD Million)

Table 84. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Application (2025-2030) & (USD Million)

Table 85. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Region (2019-2024) & (USD Million)

Table 86. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Region (2025-2030) & (USD Million)

Table 87. South America Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Type (2019-2024) & (USD Million)

Table 88. South America Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Type (2025-2030) & (USD Million)

Table 89. South America Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Application (2019-2024) & (USD Million)

Table 90. South America Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Application (2025-2030) & (USD Million)

Table 91. South America Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Country (2019-2024) & (USD Million)

Table 92. South America Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Country (2025-2030) & (USD Million)

Table 93. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Type (2019-2024) & (USD Million)

Table 94. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Type (2025-2030) & (USD Million)

Table 95. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Application (2019-2024) & (USD Million)

Table 96. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Application (2025-2030) & (USD Million)

Table 97. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Country (2019-2024) & (USD Million)

Table 98. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Country (2025-2030) & (USD Million)

Table 99. Recombinant Non-Glycosylated Proteins Biosimilars Raw Material

Table 100. Key Suppliers of Recombinant Non-Glycosylated Proteins Biosimilars Raw Materials

## List Of Figures

### LIST OF FIGURES

- Figure 1. Recombinant Non-Glycosylated Proteins Biosimilars Picture
- Figure 2. Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
- Figure 3. Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value Market Share by Type in 2023
- Figure 4. Insulin
- Figure 5. rHGH
- Figure 6. Interferon
- Figure 7. Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
- Figure 8. Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value Market Share by Application in 2023
- Figure 9. Oncology Picture
- Figure 10. Chronic Diseases Picture
- Figure 11. Autoimmune Diseases Picture
- Figure 12. Blood Disorders Picture
- Figure 13. Growth Hormone Deficiency Picture
- Figure 14. Infectious Diseases Picture
- Figure 15. Other Diseases Picture
- Figure 16. Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value, (USD Million): 2019 & 2023 & 2030
- Figure 17. Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value and Forecast (2019-2030) & (USD Million)
- Figure 18. Global Market Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
- Figure 19. Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value Market Share by Region (2019-2030)
- Figure 20. Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value Market Share by Region in 2023
- Figure 21. North America Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value (2019-2030) & (USD Million)
- Figure 22. Europe Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value (2019-2030) & (USD Million)
- Figure 23. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value (2019-2030) & (USD Million)

Figure 24. South America Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value (2019-2030) & (USD Million)

Figure 25. Middle East and Africa Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value (2019-2030) & (USD Million)

Figure 26. Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue Share by Players in 2023

Figure 27. Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023

Figure 28. Global Top 3 Players Recombinant Non-Glycosylated Proteins Biosimilars Market Share in 2023

Figure 29. Global Top 6 Players Recombinant Non-Glycosylated Proteins Biosimilars Market Share in 2023

Figure 30. Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value Share by Type (2019-2024)

Figure 31. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share Forecast by Type (2025-2030)

Figure 32. Global Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value Share by Application (2019-2024)

Figure 33. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share Forecast by Application (2025-2030)

Figure 34. North America Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value Market Share by Type (2019-2030)

Figure 35. North America Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value Market Share by Application (2019-2030)

Figure 36. North America Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value Market Share by Country (2019-2030)

Figure 37. United States Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value (2019-2030) & (USD Million)

Figure 38. Canada Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value (2019-2030) & (USD Million)

Figure 39. Mexico Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value (2019-2030) & (USD Million)

Figure 40. Europe Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value Market Share by Type (2019-2030)

Figure 41. Europe Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value Market Share by Application (2019-2030)

Figure 42. Europe Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value Market Share by Country (2019-2030)

Figure 43. Germany Recombinant Non-Glycosylated Proteins Biosimilars Consumption



Value (2019-2030) & (USD Million)

Figure 44. France Recombinant Non-Glycosylated Proteins Biosimilars Consumption

Value (2019-2030) & (USD Million)

Figure 45. United Kingdom Recombinant Non-Glycosylated Proteins Biosimilars

Consumption Value (2019-2030) & (USD Million)

Figure 46. Russia Recombinant Non-Glycosylated Proteins Biosimilars Consumption

Value (2019-2030) & (USD Million)

Figure 47. Italy Recombinant Non-Glycosylated Proteins Biosimilars Consumption

Value (2019-2030) & (USD Million)

Figure 48. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars

Consumption Value Market Share by Type (2019-2030)

Figure 49. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars

Consumption Value Market Share by Application (2019-2030)

Figure 50. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars

Consumption Value Market Share by Region (2019-2030)

Figure 51. China Recombinant Non-Glycosylated Proteins Biosimilars Consumption

Value (2019-2030) & (USD Million)

Figure 52. Japan Recombinant Non-Glycosylated Proteins Biosimilars Consumption

Value (2019-2030) & (USD Million)

Figure 53. South Korea Recombinant Non-Glycosylated Proteins Biosimilars

Consumption Value (2019-2030) & (USD Million)

Figure 54. India Recombinant Non-Glycosylated Proteins Biosimilars Consumption

Value (2019-2030) & (USD Million)

Figure 55. Southeast Asia Recombinant Non-Glycosylated Proteins Biosimilars

Consumption Value (2019-2030) & (USD Million)

Figure 56. Australia Recombinant Non-Glycosylated Proteins Biosimilars Consumption

Value (2019-2030) & (USD Million)

Figure 57. South America Recombinant Non-Glycosylated Proteins Biosimilars

Consumption Value Market Share by Type (2019-2030)

Figure 58. South America Recombinant Non-Glycosylated Proteins Biosimilars

Consumption Value Market Share by Application (2019-2030)

Figure 59. South America Recombinant Non-Glycosylated Proteins Biosimilars

Consumption Value Market Share by Country (2019-2030)

Figure 60. Brazil Recombinant Non-Glycosylated Proteins Biosimilars Consumption

Value (2019-2030) & (USD Million)

Figure 61. Argentina Recombinant Non-Glycosylated Proteins Biosimilars Consumption

Value (2019-2030) & (USD Million)

Figure 62. Middle East and Africa Recombinant Non-Glycosylated Proteins Biosimilars

Consumption Value Market Share by Type (2019-2030)

Figure 63. Middle East and Africa Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value Market Share by Application (2019-2030)

Figure 64. Middle East and Africa Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value Market Share by Country (2019-2030)

Figure 65. Turkey Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value (2019-2030) & (USD Million)

Figure 66. Saudi Arabia Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value (2019-2030) & (USD Million)

Figure 67. UAE Recombinant Non-Glycosylated Proteins Biosimilars Consumption Value (2019-2030) & (USD Million)

Figure 68. Recombinant Non-Glycosylated Proteins Biosimilars Market Drivers

Figure 69. Recombinant Non-Glycosylated Proteins Biosimilars Market Restraints

Figure 70. Recombinant Non-Glycosylated Proteins Biosimilars Market Trends

Figure 71. Porters Five Forces Analysis

Figure 72. Manufacturing Cost Structure Analysis of Recombinant Non-Glycosylated Proteins Biosimilars in 2023

Figure 73. Manufacturing Process Analysis of Recombinant Non-Glycosylated Proteins Biosimilars

Figure 74. Recombinant Non-Glycosylated Proteins Biosimilars Industrial Chain

Figure 75. Methodology

Figure 76. Research Process and Data Source

## I would like to order

Product name: Global Recombinant Non-Glycosylated Proteins Biosimilars Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Product link: <https://marketpublishers.com/r/G3A99C09280FEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3A99C09280FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



